SGN-CD33A is a next-generation anti-CD33 antibody currently in clinical trials for AML, including APL, that has demonstrated antileukemic activity with 47% blast clearance in interim analysis of the phase 1 study.100. This evidence concerns the gene CD33 and acute promyelocytic leukemia.